Table 7 Associations between the use of infliximab and patient, disease and treatment characteristics for patients with Crohn's disease (n = 1787)
From: A national survey on the patterns of treatment of inflammatory bowel disease in Canada
Characteristics | % Reporting Infliximab | Odds ratio | 95% CI |
|---|---|---|---|
Sex | |||
Male | 5.5 | Referent | |
Female | 5.6 | 1.0 | 0.7 to 1.6 |
Age | |||
16–24 | 11.6 | Referent | |
25–40 | 7.7 | 0.6 | 0.3 to 1.3 |
41–55 | 4.8 | 0.4 | 0.2 to 0.8 |
>55 | 2.7 | 0.2 | 0.1 to 0.5 |
Disease activity | |||
Inactive | 1.8 | Referent | |
Mild | 2.3 | 1.3 | 0.5 to 3.3 |
Moderate | 5.4 | 3.0 | 1.3 to 7.4 |
Severe | 21.1 | 14.4 | 5.7 to 36.3 |
Prior hospitalization | |||
No | 1.7 | Referent | |
Yes | 6.3 | 3.9 | 1.6 to 9.6 |
Surgery within the past 2 years | |||
No | 4.6 | Referent | |
Yes | 11.4 | 2.7 | 1.7 to 4.2 |
IV Steroids in past 12 months | |||
No | 4.8 | Referent | |
Yes | 18.9 | 4.6 | 2.6 to 8.2 |
PO Steroids in past 12 months | |||
No | 2.5 | Referent | |
Yes | 11.2 | 5.0 | 3.2 to 7.8 |
PO 6 MP/Azathioprine in past 12 months | |||
No | 3.6 | Referent | |
Yes | 11.8 | 3.6 | 2.4 to 5.4 |